GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.

Whether it's about promoting protein or smaller portions, the restaurant industry is preparing for a shift in consumer ...

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. On Jan. 13, the FDA ...

Glucagon-like peptide-1 receptor agonists (GLP-1s) are a class of medication that includes Ozempic®, Wegovy®, and Saxenda®. Some GLP-1s are diabetes drugs, but you can also take a GLP-1 for weight ...

Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...

In a new trial, people who switched to the experimental daily GLP-1 pill orforglipron were able to keep off most of the weight they had lost taking Wegovy or Zepbound. People who switched from Wegovy ...

GLP-1 medications have reached a level of household penetration that food and beverage brands can no longer ignore, but the impact on grocery sales is unfolding more gradually than some might expect.

Telehealth company eMed has partnered with CVS Caremark to offer a GLP-1 benefit model that lets employers subsidize weight loss medications without covering the full cost, Axios reported Feb. 16. The ...

The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce. Many drugs offer comparable weight loss. Healthcare companies have ...

More people are paying out-of-pocket for GLP-1 weight loss drugs — and more retailers are offering discounts on Zepbound, Ozempic, and Wegovy. Walmart will offer in-store pickup for Zepbound at ...

A comprehensive meta-analysis of 91 clinical trials involving more than 100,000 patients showed no increased risk for suicidal ideation or other psychiatric adverse events with GLP-1 receptor agonist ...